GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
Item 2.02 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description |
| 99.1 | Press Release dated August14, 2017 |
GALECTIN THERAPEUTICS INC ExhibitEX-99.1 2 d398015dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update 80% of the patients enrolled have completed all 52 weeks of infusions and 99% of the doses have already been administered in the NASH Cirrhosis,…To view the full exhibit click here
About GALECTIN THERAPEUTICS INC. (NASDAQ:GALT)
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies. GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Recent Trading Information
GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) closed its last trading session down -0.09 at 1.72 with 174,200 shares trading hands.
